Near-term growth catalysts:
• Major announcements and strategic partnerships to be completed for MXC’s Australian medical cannabis genetics and breeding research, clinical trials, and production strategy
• Plans to commence first Australian MC clinical trials in 2017 – with leading medical institutions
Sentiment - accumulate
Ann: Investor Presentation - March 2017, page-2
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.58M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 30.0¢ | $2.567K | 8.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 47481 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8026 | 2 |
View Market Depth
| Last trade - 15.53pm 21/06/2024 (20 minute delay) ? |
| RGT (ASX) Chart |